After BTIG and Needham gave G1 Therapeutics Inc (NASDAQ: GTHX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Edward White maintained a Buy rating on G1 Therapeutics Inc today and set a price target of $79. The company’s shares opened today at $43.39.
“We base our $79 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC.”
According to TipRanks.com, White is a 5-star analyst with an average return of 18.5% and a 46.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Currently, the analyst consensus on G1 Therapeutics Inc is a Strong Buy with an average price target of $78.33.
Based on G1 Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.87 million. In comparison, last year the company had a GAAP net loss of $15.6 million.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage pharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.